Feed NVS
NV

Novartis

NVS · NYSE

$139.02 +1.36% (+$1.86)
1M -8.54%
Market Cap $264.2B
P/E Ratio 20.71x
Div. Yield 3.41%
ROE 29.93%

Bulios Fair Price

$204.41

47.0% upside

Trenutna cena

$139.02

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica NVS trenutno podcenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Moderate
6/9
Valuation
58 /100
Fair
P/FCF 16.70x
P/E 20.71x
P/B 6.36x
Growth
69 /100
Growing
FCF growth 13.81%
EPS growth 31.39%
Book val. growth 8.05%
Profitability
100 /100
Strong
Op. margin 30.54%
Gross margin 74.44%
FCF margin 28.43%
Quality
79 /100
Excellent
ROA 10.46%
ROIC 13.93%
Asset turnover 0.46x
Debt
61 /100
Moderate
Int. coverage 12.17x
Debt/Equity 1.18x
Net debt/EBITDA 1.86x
Stability
64 /100
Moderate
EPS volatility 72.86%
Beta 0.46x
Profitable years 6

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o NVS
Online

O podjetju

Novartis AG is a Swiss global pharmaceutical company with a broad portfolio of medicines and healthcare products. The company is one of the leading players in the pharmaceutical industry and operates worldwide. Novartis focuses on the development, manufacturing, and distribution of innovative medicines in various therapeutic areas, including oncology, cardiology, ophthalmology, neurology, and others. The company also specializes in the production and sale of generic drugs. Novartis dedicates significant efforts to research and development of new treatment options to help improve the quality of life for patients around the world. The company actively collaborates with medical professionals and institutions to ensure the best care for patients. Novartis AG (NVS) shares are an attractive choice for investors who follow the pharmaceutical industry and seek investment opportunities in a reputable company with a rich medical portfolio and a long history of innovation.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Vasant Narasimhan

Employees

75,267

Headquarters

Basel

Prihajajoči dogodki

27 OKT.

Earnings

Upcoming earnings report

42d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.